{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:45:53Z","timestamp":1778507153584,"version":"3.51.4"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The treatment for patients with colorectal cancer with metastases to the peritoneum is complex and may involve both surgery and chemotherapy. Circulating tumor cells (CTCs) have been poorly investigated in peritoneal metastatic colorectal cancer. The aim of the study is to examine the role of CTCs as a biomarker for monitoring disease progression, treatment response, and residual disease using CellMate \u2013 a new promising in vitro diagnostic platform technology.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and methods:<\/jats:title>\n            <jats:p>The authors prospectively followed the clinical outcomes of 46 patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with peritoneal metastases and examined whether CTCs were present the week of surgery. The CTC measurements were made with the CellMate technology, which is a platform technology to detect CTCs based on the difference in biomechanical properties compared to blood resident cells. The study was registered online (ClinicalTrials.gov).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>CTCs were detected in 17 (37%) patients. The presence of CTCs was associated with shorter recurrence-free survival and overall survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Both recurrence-free survival (HR 4.00, 95% CI: 1.15\u201313.9; <jats:italic toggle=\"yes\">P<\/jats:italic>=0.029) and overall survival (HR 5.91; 95% CI: 1.18\u201329.7; <jats:italic toggle=\"yes\">P<\/jats:italic>=0.03) were significantly worse if CTCs were detected after neoadjuvant treatment. In the subgroup of patients with CTCs detected, adjuvant therapy tended to improve the prognosis while in CTC negative patients it did not.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Pending a prospective multicenter trial to validate these findings, CTCs may in the future be used as a dynamic personalized biomarker for prognostication, predicting response to therapy, and for monitoring disease progression in colorectal cancer with metastases to the peritoneum.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/js9.0000000000001906","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T04:00:09Z","timestamp":1720497609000},"page":"7187-7195","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Clinical significance of circulating tumor cells in colorectal cancer with peritoneal metastases: a prospective cohort study using a novel method for monitoring treatment response, and assessing minimal residual disease"],"prefix":"10.1097","volume":"110","author":[{"given":"Petter","family":"Fr\u00fchling","sequence":"first","affiliation":[{"name":"Department of Surgical Sciences, Section of Surgery, Uppsala University, Akademiska Sjukhuset, Uppsala"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louice","family":"Moberg","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, Section of Surgery, Uppsala University, Akademiska Sjukhuset, Uppsala"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lana","family":"Ghanipour","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, Section of Surgery, Uppsala University, Akademiska Sjukhuset, Uppsala"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helgi","family":"Birgisson","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, Section of Surgery, Uppsala University, Akademiska Sjukhuset, Uppsala"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilhelm","family":"Graf","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, Section of Surgery, Uppsala University, Akademiska Sjukhuset, Uppsala"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christer","family":"Ericsson","sequence":"additional","affiliation":[{"name":"iCellate Medical AB, KI Science Park, Industriv\u00e4gen 1, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.H.","family":"Cashin","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, Section of Surgery, Uppsala University, Akademiska Sjukhuset, Uppsala"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,11]]},"reference":[{"key":"R1-20250824","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018","volume":"103","author":"Ferlay","year":"2018","journal-title":"Eur J Cancer"},{"key":"R2-20250824","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: an overview","volume":"149","author":"Ferlay","year":"2021","journal-title":"Int J Cancer"},{"key":"R3-20250824","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.apsb.2015.07.005","article-title":"Cancer metastases: challenges and opportunities","volume":"5","author":"Guan","year":"2015","journal-title":"Acta Pharm Sin B"},{"key":"R4-20250824","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13045-019-0760-3","article-title":"Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications","volume":"12","author":"Lin","year":"2019","journal-title":"J Hematol Oncol"},{"key":"R5-20250824","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10585-015-9719-0","article-title":"Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases","volume":"32","author":"van der Geest","year":"2015","journal-title":"Clin Exp Metastasis"},{"key":"R6-20250824","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/BF01789207","article-title":"A perspective on clinical research strategies in carcinoma of the large bowel","volume":"15","author":"Sugarbaker","year":"1991","journal-title":"World J Surg"},{"key":"R7-20250824","first-page":"256","article-title":"Clinical delivery system for intraperitoneal hyperthermic chemotherapy","volume":"40","author":"Spratt","year":"1980","journal-title":"Cancer Res"},{"key":"R8-20250824","doi-asserted-by":"crossref","first-page":"55657","DOI":"10.18632\/oncotarget.17497","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of current evidence","volume":"8","author":"Huang","year":"2017","journal-title":"Oncotarget"},{"key":"R9-20250824","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00000658-199501000-00004","article-title":"Peritonectomy procedures","volume":"221","author":"Sugarbaker","year":"1995","journal-title":"Ann Surg"},{"key":"R10-20250824","doi-asserted-by":"crossref","first-page":"104237","DOI":"10.1016\/j.ebiom.2022.104237","article-title":"Circulating tumor cell isolation for cancer diagnosis and prognosis","volume":"83","author":"Deng","year":"2022","journal-title":"EBioMedicine"},{"key":"R11-20250824","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41392-021-00817-8","article-title":"Circulating tumor cells: biology and clinical significance","volume":"6","author":"Lin","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"R12-20250824","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1038\/s41416-023-02228-8","article-title":"Circulating tumour cells in gastrointestinal cancers: food for thought?","volume":"128","author":"Asawa","year":"2023","journal-title":"Br J Cancer"},{"key":"R13-20250824","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/s41416-022-01742-5","article-title":"Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity","volume":"126","author":"Laoukili","year":"2022","journal-title":"Br J Cancer"},{"key":"R14-20250824","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1002\/bjs.10788","article-title":"Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases","volume":"105","author":"Ubink","year":"2018","journal-title":"Br J Surg"},{"key":"R15-20250824","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.bjc.6602678","article-title":"REporting recommendations for tumour MARKer prognostic studies (REMARK)","volume":"93","author":"McShane","year":"2005","journal-title":"Br J Cancer"},{"key":"R17-20250824","doi-asserted-by":"crossref","first-page":"734595","DOI":"10.3389\/fgene.2021.734595","article-title":"Circulating tumor cells (CTCs): a unique model of cancer metastases and non-invasive biomarkers of therapeutic response","volume":"12","author":"Liu","year":"2021","journal-title":"Front Genet"},{"key":"R18-20250824","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ctrv.2011.04.002","article-title":"Epithelial cell adhesion molecule expression (CD326) in cancer: a short review","volume":"38","author":"Patriarca","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"R19-20250824","doi-asserted-by":"crossref","first-page":"13582","DOI":"10.3390\/ijms232113582","article-title":"Circulating tumor cells in colorectal cancer: detection systems and clinical utility","volume":"23","author":"Petrik","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R20-20250824","first-page":"3","article-title":"Screening circulating tumor cells as a non-invasive cancer test in 1,585 asymptomatic adults (ICELLATE1)","volume":"07","author":"Castro","year":"2018","journal-title":"J Integrat Oncol"},{"key":"R21-20250824","doi-asserted-by":"crossref","first-page":"4653109","DOI":"10.1155\/2018\/4653109","article-title":"Screening circulating tumor cells as a noninvasive cancer test in 3388 individuals from high-risk groups (ICELLATE2)","volume":"2018","author":"Castro","year":"2018","journal-title":"Dis Markers"},{"key":"R22-20250824","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","article-title":"Liquid biopsy enters the clinic - implementation issues and future challenges","volume":"18","author":"Ignatiadis","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"R23-20250824","doi-asserted-by":"crossref","first-page":"e15914","DOI":"10.15252\/emmm.202215914","article-title":"The molecular biology of peritoneal metastatic disease","volume":"15","author":"Bootsma","year":"2023","journal-title":"EMBO Mol Med"},{"key":"R24-20250824","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.5306\/wjco.v12.i12.1169","article-title":"Detection of circulating tumour cells in colorectal cancer: emerging techniques and clinical implications","volume":"12","author":"Yadav","year":"2021","journal-title":"World J Clin Oncol"},{"key":"R25-20250824","doi-asserted-by":"crossref","first-page":"7407190","DOI":"10.1155\/2019\/7407190","article-title":"Mechanisms of metastasis in colorectal cancer and metastatic organotropism: hematogenous versus peritoneal spread","volume":"2019","author":"Pretzsch","year":"2019","journal-title":"J Oncol"},{"key":"R26-20250824","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1470-2045(14)70069-5","article-title":"Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data","volume":"15","author":"Bidard","year":"2014","journal-title":"Lancet Oncol"},{"key":"R27-20250824","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"R28-20250824","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1126\/science.1203543","article-title":"A perspective on cancer cell metastasis","volume":"331","author":"Chaffer","year":"2011","journal-title":"Science"},{"key":"R29-20250824","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1615\/CritRevOncog.v18.i1-2.40","article-title":"On the origin of cancer metastasis","volume":"18","author":"Seyfried","year":"2013","journal-title":"Crit Rev Oncog"},{"key":"R30-20250824","article-title":"Unraveling metastasis with circulating tumor cells","author":"Paxton","year":"2014","journal-title":"CAP Today"},{"key":"R31-20250824","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.molonc.2015.12.002","article-title":"Challenges in circulating tumor cell detection by the CellSearch system","volume":"10","author":"Andree","year":"2016","journal-title":"Mol Oncol"},{"issue":"16_suppl","key":"R32-20250824","doi-asserted-by":"crossref","first-page":"e15021","DOI":"10.1200\/JCO.2022.40.16_suppl.e15021","article-title":"Circulating tumor cells as a biomarker for monitoring: disease progression, treatment response, and minimal residual disease","volume":"40","author":"Nirmal Vivek Raut","year":"2022","journal-title":"J Clin Oncol"},{"key":"R33-20250824","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.surg.2015.09.013","article-title":"Prognostic factor analysis of circulating tumor cells in peripheral blood of patients with peritoneal carcinomatosis of colon cancer origin treated with cytoreductive surgery plus an intraoperative hyperthermic intraperitoneal chemotherapy procedure (CRS + HIPEC)","volume":"159","author":"Melero","year":"2016","journal-title":"Surgery"},{"key":"R34-20250824","doi-asserted-by":"crossref","first-page":"R71","DOI":"10.1186\/bcr3180","article-title":"Biomarkers characterization of circulating tumour cells in breast cancer patients","volume":"14","author":"Nadal","year":"2012","journal-title":"Breast Cancer Res"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000001906","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T19:00:16Z","timestamp":1756062016000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000001906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,5]]},"references-count":33,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000001906","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,5]]},"assertion":[{"value":"2024-04-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}